Enliven Therapeutics, Inc. (ELVN) — Financial statements
Income statement, balance sheet, and cash flow for Enliven Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.26 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -0.26 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 86↑6.3% | 81↑25.1% | 65↑108.2% | 31↑51.5% | 20 | |
| General & Administrative Expenses | 34↑42.2% | 24↑25.4% | 19↑144.0% | 8↑81.2% | 4 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 34↑42.2% | 24↑25.4% | 19↑144.0% | 8↑81.2% | 4 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 119↑14.2% | 105↑25.2% | 84↑115.3% | 39↑56.7% | 25 | |
| Total Costs & Expenses | 120↑14.4% | 105↑25.2% | 84↑115.3% | 39↑56.7% | 25 | |
| Operating Results | ||||||
| Operating Income | -120↓14.4% | -105↓25.2% | -84↓115.3% | -39↓56.7% | -25 | |
| Depreciation & Amortization | 0.26↓17.0% | 0.32↑6.7% | 0.30↑38.1% | 0.22↑87.0% | 0.12 | |
| EBITDA | -119↓14.5% | -104↓25.2% | -83↓115.8% | -39↓56.5% | -25 | |
| EBIT | -120↓14.4% | -105↓25.2% | -84↓115.3% | -39↓56.7% | -25 | |
| Interest & Other Income | ||||||
| Net Interest Income | 16↑7.5% | 15↑24.4% | 12↑960.0% | 1↑5031.8% | 0.02 | |
| Interest Income | 16↑7.5% | 15↑24.4% | 12↑960.0% | 1↑5031.8% | 0.02 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 16↑1.3% | 16↑32.0% | 12↑958.0% | 1↑5031.8% | 0.02 | |
| Income Before Tax | -104↓16.8% | -89↓24.0% | -72↓90.1% | -38↓52.2% | -25 | |
| Income Tax Expense | 0.00↓100.0% | 0.23 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -104↓16.5% | -89↓24.4% | -72↓90.1% | -38↓52.2% | -25 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -104↓16.5% | -89↓24.4% | -72↓90.1% | -38↓52.2% | -25 | |
| Bottom-Line Net Income | -104↓16.5% | -89↓24.4% | -72↓90.1% | -38↓52.2% | -25 | |
| EPS (Basic) | -1.83↑3.2% | -1.89↑6.0% | -2.01↑66.7% | -6.03↓90.2% | -3.17 | |
| EPS (Diluted) | -1.83↑3.2% | -1.89↑6.0% | -2.01↑66.7% | -6.03↓90.2% | -3.17 | |
| Weighted Average Shares | 57↑20.4% | 47↑32.4% | 36↑468.8% | 6↓20.0% | 8 | |
| Weighted Average Diluted Shares | 57↑20.4% | 47↑32.4% | 36↑468.8% | 6↓20.0% | 8 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.